[Form 4] Trilogy Metals Inc. Insider Trading Activity
Rhea-AI Filing Summary
Trilogy Metals Inc. reported a new stock option grant to a director. On 12/11/2025, the director received a Director Stock Option covering 65,000 common shares at an exercise price of $4.61 per share. The options become exercisable on 12/11/2025 and expire on 12/10/2030, giving the holder the right to buy Trilogy Metals common shares at this fixed price during that period.
The exercise price of $4.61 was derived from a Canadian exercise price of C$6.35 using an exchange rate of C$1.3774 = US$1.00. After this grant, the reporting person beneficially owns 65,000 derivative securities, all held directly. This filing reflects routine equity-based compensation for board service rather than a sale or purchase of existing shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) | 65,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. Converted from Canadian exercise price of C$6.35 using an exchange rate of C$1.3774 = US$1.00.
FAQ
What insider transaction did Trilogy Metals (TMQ) report in this Form 4?
What is the exercise price of the new Trilogy Metals (TMQ) director stock options?
When do the Trilogy Metals (TMQ) director stock options vest and expire?
How many Trilogy Metals (TMQ) derivative securities does the reporting person own after this transaction?
What type of security underlies the Trilogy Metals (TMQ) director stock option grant?
Who signed the Trilogy Metals (TMQ) Form 4 reporting this option grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.